Clinical Scenarios for Discordant Anti-Xa
Anti-Xa test measures the activity of heparin against the activity of activated coagulation factor X; significant variability of anti-Xa levels in common clinical scenarios has been observed. Objective. To review the most common clinical settings in which anti-Xa results can be bias. Evidence Review...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2016/4054806 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553997532135424 |
|---|---|
| author | Jesus Vera-Aguilera Hindi Yousef Diego Beltran-Melgarejo Teng Hugh Teng Ramos Jan Mary Mok Carlos Vera-Aguilera Eduardo Moreno-Aguilera |
| author_facet | Jesus Vera-Aguilera Hindi Yousef Diego Beltran-Melgarejo Teng Hugh Teng Ramos Jan Mary Mok Carlos Vera-Aguilera Eduardo Moreno-Aguilera |
| author_sort | Jesus Vera-Aguilera |
| collection | DOAJ |
| description | Anti-Xa test measures the activity of heparin against the activity of activated coagulation factor X; significant variability of anti-Xa levels in common clinical scenarios has been observed. Objective. To review the most common clinical settings in which anti-Xa results can be bias. Evidence Review. Guidelines and current literature search: we used PubMed, Medline, Embase, and MEDION, from 2000 to October 2013. Results. Anti-Xa test is widely used; however the assay underestimates heparin concentration in the presence of significant AT deficiency, pregnancy, end stage renal disease, and postthrombolysis and in patients with hyperbilirubinemia; limited published data evaluating the safety and effectiveness of anti-Xa assays for managing UH therapy is available. Conclusions and Relevance. To our knowledge this is the first paper that summarizes the most common causes in which this assay can be affected, several “day to day” clinical scenarios can modify the outcomes, and we concur that these rarely recognized scenarios can be affected by negative outcomes in the daily practice. |
| format | Article |
| id | doaj-art-272d54d360fd4c4ea15fbe54b43b296d |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-272d54d360fd4c4ea15fbe54b43b296d2025-02-03T05:52:39ZengWileyAdvances in Hematology1687-91041687-91122016-01-01201610.1155/2016/40548064054806Clinical Scenarios for Discordant Anti-XaJesus Vera-Aguilera0Hindi Yousef1Diego Beltran-Melgarejo2Teng Hugh Teng3Ramos Jan4Mary Mok5Carlos Vera-Aguilera6Eduardo Moreno-Aguilera7Internal Medicine, Texas Tech University Health Sciences Center at the Permian Basin, 800 W. 4th Street, Odessa, TX 79763, USAInternal Medicine, Texas Tech University Health Sciences Center at the Permian Basin, 800 W. 4th Street, Odessa, TX 79763, USAInternal Medicine, Texas Tech University Health Sciences Center at the Permian Basin, 800 W. 4th Street, Odessa, TX 79763, USATexas Tech University Health Sciences Center School of Pharmacy at Dallas, 5920 Forrest Park Lane, Suite 400, Dallas, TX 75235, USAUniversity of the Incarnate Word Feik School of Pharmacy, 4301 Broadway, San Antonio, TX 78209, USAInternal Medicine, Texas Tech University Health Sciences Center at the Permian Basin, 800 W. 4th Street, Odessa, TX 79763, USADepartamento de Biología Celular y Tisular, Facultad de Medicina, UNAM, 04510 México, DF, MexicoServicio de Gastrocirugía, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, 06720 México, DF, MexicoAnti-Xa test measures the activity of heparin against the activity of activated coagulation factor X; significant variability of anti-Xa levels in common clinical scenarios has been observed. Objective. To review the most common clinical settings in which anti-Xa results can be bias. Evidence Review. Guidelines and current literature search: we used PubMed, Medline, Embase, and MEDION, from 2000 to October 2013. Results. Anti-Xa test is widely used; however the assay underestimates heparin concentration in the presence of significant AT deficiency, pregnancy, end stage renal disease, and postthrombolysis and in patients with hyperbilirubinemia; limited published data evaluating the safety and effectiveness of anti-Xa assays for managing UH therapy is available. Conclusions and Relevance. To our knowledge this is the first paper that summarizes the most common causes in which this assay can be affected, several “day to day” clinical scenarios can modify the outcomes, and we concur that these rarely recognized scenarios can be affected by negative outcomes in the daily practice.http://dx.doi.org/10.1155/2016/4054806 |
| spellingShingle | Jesus Vera-Aguilera Hindi Yousef Diego Beltran-Melgarejo Teng Hugh Teng Ramos Jan Mary Mok Carlos Vera-Aguilera Eduardo Moreno-Aguilera Clinical Scenarios for Discordant Anti-Xa Advances in Hematology |
| title | Clinical Scenarios for Discordant Anti-Xa |
| title_full | Clinical Scenarios for Discordant Anti-Xa |
| title_fullStr | Clinical Scenarios for Discordant Anti-Xa |
| title_full_unstemmed | Clinical Scenarios for Discordant Anti-Xa |
| title_short | Clinical Scenarios for Discordant Anti-Xa |
| title_sort | clinical scenarios for discordant anti xa |
| url | http://dx.doi.org/10.1155/2016/4054806 |
| work_keys_str_mv | AT jesusveraaguilera clinicalscenariosfordiscordantantixa AT hindiyousef clinicalscenariosfordiscordantantixa AT diegobeltranmelgarejo clinicalscenariosfordiscordantantixa AT tenghughteng clinicalscenariosfordiscordantantixa AT ramosjan clinicalscenariosfordiscordantantixa AT marymok clinicalscenariosfordiscordantantixa AT carlosveraaguilera clinicalscenariosfordiscordantantixa AT eduardomorenoaguilera clinicalscenariosfordiscordantantixa |